{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:12:23Z","timestamp":1793913143598,"version":"4.8.0"},"reference-count":29,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Int Assoc Provid AIDS Care"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of the research<\/jats:title>\n                    <jats:p>To compare incident hypertension rates across antiretroviral therapy regimens among adults with HIV in routine clinical care in the US-based OPERA cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Major findings<\/jats:title>\n                    <jats:p>The hypertension incidence rate was 4.16 per 100 person-years (95% CI: 3.75, 4.61) among 3220 ART-na\u00efve individuals, and 4.60 (95% CI: 3.99, 5.30) among 1442 ART-experienced individuals. There was no statistically significant difference in incident hypertension between regimens at the class-level (integrase inhibitor with\/without tenofovir alafenamide (TAF), boosted protease inhibitor, and non-nucleoside reverse transcriptase inhibitor) nor the drug-level (dolutegravir three-drug regimen with\/without TAF, dolutegravir\/lamivudine, bictegravir\/emtricitabine\/TAF, and boosted darunavir with TAF three-drug regimen).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this large cohort representing routine clinical care in the USA, classes of antiretrovirals and specific agent combinations with or without TAF were not statistically significantly associated with incident hypertension. Other factors are likely to be more important drivers of hypertension than antiretroviral therapy selection in people with HIV.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/23259582261445148","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T13:32:33Z","timestamp":1776951153000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Incident Hypertension with Antiretroviral Therapy in the OPERA Cohort"],"prefix":"10.1177","volume":"25","author":[{"given":"Gerald","family":"Pierone Jr","sequence":"first","affiliation":[{"name":"Whole Family Health Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-4835","authenticated-orcid":false,"given":"Laurence","family":"Brunet","sequence":"additional","affiliation":[{"name":"Epividian, Inc., Raleigh, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1556-811X","authenticated-orcid":false,"given":"Jennifer S","family":"Fusco","sequence":"additional","affiliation":[{"name":"Epividian, Inc., Raleigh, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip C","family":"Lackey","sequence":"additional","affiliation":[{"name":"Wake Forest University School of Medicine*"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B","family":"Wohlfeiler","sequence":"additional","affiliation":[{"name":"AIDS Healthcare Foundation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas T","family":"Dieterich","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassidy","family":"Henegar","sequence":"additional","affiliation":[{"name":"ViiV Healthcare"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vani","family":"Vannappagari","sequence":"additional","affiliation":[{"name":"ViiV Healthcare"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryn","family":"Jones","sequence":"additional","affiliation":[{"name":"ViiV Healthcare"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemiek","family":"de Ruiter","sequence":"additional","affiliation":[{"name":"ViiV Healthcare"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory P","family":"Fusco","sequence":"additional","affiliation":[{"name":"Epividian, Inc., Raleigh, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,4,23]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-019-0244-2"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(02)11911-8"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(14)60685-1"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYP.0000000000000065"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-021-01978-7"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpae048"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-020-01089-3"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000002446"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-019-0956-5"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12639"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13273"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpae078"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(23)00328-4"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.32968"},{"key":"e_1_3_3_16_2","unstructured":"Kileel EM Malvestutto CD Zanni MV et al. 2025. [Poster 838] Risk of obesity cardiometabolic disease and MACE after switching to an integrase inhibitor in REPRIEVE. 2025."},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab537"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-ICAR-2024.50"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-025-00732-w"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26268"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26216"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101836"},{"key":"e_1_3_3_23_2","unstructured":"Shamu T Egger M Mudzviti T Chimbetete C Manasa J Anderegg N. 2023. Blood pressure among people living with HIV transitioning from efavirenz-to dolutegravir-based ART: a cohort study from Zimbabwe [abstract EPB0191]. 2023."},{"key":"e_1_3_3_24_2","unstructured":"Venter F Sokhela S Bosch B et al. 2023. Risks of hypertension with first-line dolutegravir (DTG) and tenofovir alafenamide (TAF) in the NAMSAL and ADVANCE trials [abstract OALBB0504]. 2023."},{"key":"e_1_3_3_25_2","unstructured":"Patel P Milinkovic A Grove R et al. 2023. Evaluation of incident hypertension and blood pressure changes among people living with HIV-1 (PLWH) receiving dolutegravir (DTG)-based regimens or comparator antiretroviral therapy (CAR) in randomized clinical trials through 96 weeks [abstract LBEPB12]. 2023."},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae631.773"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad297"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040296"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae256"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw804"}],"container-title":["Journal of the International Association of Providers of AIDS Care (JIAPAC)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23259582261445148","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/23259582261445148","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23259582261445148","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:51:09Z","timestamp":1777503069000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/23259582261445148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":29,"alternative-id":["10.1177\/23259582261445148"],"URL":"https:\/\/doi.org\/10.1177\/23259582261445148","relation":{},"ISSN":["2325-9582","2325-9582"],"issn-type":[{"value":"2325-9582","type":"print"},{"value":"2325-9582","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"article-number":"23259582261445148"}}